HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. is headquartered in Gatineau, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-406-1852
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$33.53 million
Profitability
Miscellaneous
Employees374
Next Earnings DateN/A
OptionableOptionable
Hexo (TSE:HEXO) Frequently Asked Questions
What is Hexo's stock symbol?
Hexo trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HEXO."
What price target have analysts set for HEXO?
6 Wall Street analysts have issued twelve-month target prices for Hexo's shares. Their forecasts range from C$7.00 to C$14.00. On average, they expect Hexo's stock price to reach C$9.59 in the next year. View Analyst Price Targets for Hexo.
What is the consensus analysts' recommendation for Hexo?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hexo in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hexo.
Has Hexo been receiving favorable news coverage?
Press coverage about HEXO stock has been trending negative on Friday, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hexo earned a news impact score of -2.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Hexo.
Who are some of Hexo's key competitors?
Some companies that are related to Hexo include Hikma Pharmaceuticals (HIK), Evotec (EVT), Aphria (APHA), Knight Therapeutics (GUD), Green Organic Dutchman (TGOD), OrganiGram (OGI), Supreme Cannabis (FIRE), HLS Therapeutics (HLS), Flowr (FLWR), CannTrust (TRST), Benchmark (BMK), ICC Labs (ICC), Shield Therapeutics (STX), Althea Group (AGH) and WeedMD (WMD).
What other stocks do shareholders of Hexo own?
Who are Hexo's key executives?
Hexo's management team includes the folowing people:
- Mr. Sebastien G. St-Louis, Co-Founder, Pres, CEO & Director (Age 35)
- Mr. Adam Miron, Co-founder, Chief Brand Officer & Director (Age 35)
- Mr. Ed Chaplin, CFO & Corp. Sec. (Age 49)
- Mr. James McMillan, VP of Bus. Devel. (Age 51)
- Dr. Terence Lake DVM, Vice-Pres of Corp. & Social Responsibility
How do I buy shares of Hexo?
Shares of HEXO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How big of a company is Hexo?
What is Hexo's official website?
How can I contact Hexo?
The company can be reached via phone at 844-406-1852.
MarketBeat Community Rating for Hexo (TSE HEXO)
MarketBeat's community ratings are surveys of what our community members think about Hexo and other stocks. Vote "Outperform" if you believe HEXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEXO will underperform the S&P 500 over the long term. You may vote once every thirty days.
